Уноси · Publikacije Univerziteta u Banjoj Luci

Unosi

Population Pharmacokinetic Model of Linezolid and Probability of Target Attainment in Patients with COVID-19-Associated Acute Respiratory Distress Syndrome on Veno-Venous Extracorporeal Membrane Oxygenation—A Step toward Correct Dosing (2024-02)

D. Milaković, T. Kovačević, P. Kovačević, V. Barišić, S. Avram, S. Dragić, B. Zlojutro, D. Momčičević, B. Miljković, K. Vučićević, Population Pharmacokinetic Model of Linezolid and Probability of Target Attainment in Patients with COVID-19-Associated Acute Respiratory Distress Syndrome on Veno-Venous Extracorporeal Membrane Oxygenation—A Step toward Correct Dosing, PHARMACEUTICS, Vol. 16, No. 2, Feb, 2024
Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study (2024-05)

P. Kovačević, D. Milaković, T. Kovačević, V. Barišić, S. Dragić, B. Zlojutro, B. Miljković, K. Vučićević, Z. Rizwan, Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study, NAUNYN-SCHMIEDEBERG`S ARCHIVES OF PHARMACOLOGY, Vol. 397, pp. 7747 - 7756, May, 2024
Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics) (2018)

S. Vezmar Kovačević, K. Vučićević, V. Topić-Vučenović, Z. Rajkovača, B. Miljković, Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics), Arhiv za farmaciju, Vol. 68, No. 6, pp. 1071 - 1083, 2018
Izazovi i stavovi o doziranju radioaktivnog joda u terapiji benignih oboljenja štitne žlijezde (2018-04)

V. Topić Vučenović, Z. Rajkovača, S. Vezmar Kovačević, B. Miljković, K. Vučićević, Izazovi i stavovi o doziranju radioaktivnog joda u terapiji benignih oboljenja štitne žlijezde, Arhiv za farmaciju, Vol. 67, pp. 333 - 344, Apr, 2018
Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach (2018-05)

V. Topić Vučenović, Z. Rajkovača, D. Jelić, D. Stanimirović, G. Vuleta, B. Miljković, K. Vučićević, Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, Vol. 74, No. 8, pp. 1037 - 1045, May, 2018
Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics) (2018-12)

S. Vezmar Kovačević, K. Vučićević, V. Topić Vučenović, Z. Rajkovača, B. Miljković, Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics), Arhiv za farmaciju, Vol. 68, No. 6, pp. 1071 - 1083, Dec, 2018
Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients (2020)

T. Kovačević, B. Miljkovic, P. Kovačević, S. Dragic, D. Momcicevic, S. Avram, M. Jovanovic, K. Vucicevic, Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients, JOURNAL OF CRITICAL CARE, pp. 116 - 121, 2020
Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients (2020-06)

T. Kovačević, B. Miljkovic, P. Kovačević, S. Dragić, D. Momčičević, S. Avrama, M. Jovanovic, K. Vucicevic, Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients, JOURNAL OF CRITICAL CARE, Vol. 55, pp. 116 - 121, Jun, 2020
Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice (2021-08)

M. Roganović, A. Homšek, M. Jovanović, V. Topić Vučenović, M. Ćulafić, B. Miljković, K. Vučićević, Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice, Arhiv za farmaciju, Vol. 71, No. 4, pp. 336 - 353, Aug, 2021
Nonlinear mixed effects modelling approach for investigation of 131I in patients with benign thyroid disease (2017)

V. Topić Vučenović, k. vučičević, z. rajkovača, d. stanimirović, D. Jelić, g. vuleta, b. miljković, Nonlinear mixed effects modelling approach for investigation of 131I in patients with benign thyroid disease, 2017
Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease (2017-06)

V. Topić Vučenović, K. Vučićević, Z. Rajkovača, D. Stanimirović, G. Vuleta, D. Jelić, B. Miljković, Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease, Jun, 2017
Investigation of influence of anti-thyroid drug discontinuation time on 131I biokinetics in patients with benign thyroid disease (2017-10)

V. Topić, K. Vučićević, Z. Rajkovača, D. Stanimirović, G. Vuleta, D. Jelić, B. Miljković, Investigation of influence of anti-thyroid drug discontinuation time on 131I biokinetics in patients with benign thyroid disease, Eur J Nucl Med Mol Imaging. 2017; 44 (Suppl 2), pp. S809 - S809, Oct, 2017
Investigation of the influence of functional thyroide volumen on the probability of 131 I therapy outcome in patients with benign thyroide disease (2018)

V. Topić Vučenović, D. Jelić, Z. Rajkovača, S. Miljković, K. Vučićević, Investigation of the influence of functional thyroide volumen on the probability of 131 I therapy outcome in patients with benign thyroide disease, 2018
Prediction of the radioiodine therapy outcomes in patients with benign thyroid disease based on pre-therapeutic dosimetry (2018-09)

V. Topić Vučenović, D. Jelić, Z. Rajkovača, B. Miljković, K. Vučićević, Prediction of the radioiodine therapy outcomes in patients with benign thyroid disease based on pre-therapeutic dosimetry, Kongres nuklearne medicine Srbije sa međunarodnim učešćem 2018, Program i zbornik sažetaka, pp. 135 - 135, Sep, 2018
Integrating Clopidogrel's First-Pass Effect in a Joint Semi-Physiological Population Pharmacokinetic Model of the Drug and Its Inactive Carboxylic Acid Metabolite (2024-05)

Z. Pejčić, V. Topić Vučenović, B. Miljković, K. Vučićević, Integrating Clopidogrel's First-Pass Effect in a Joint Semi-Physiological Population Pharmacokinetic Model of the Drug and Its Inactive Carboxylic Acid Metabolite, PHARMACEUTICS, May, 2024
Review of lists and recommendations for interchangeability of medicines across selected European countries (2024-08)

Z. Pejčić, V. Topić Vučenović, B. Miljković, K. Vučićević, Review of lists and recommendations for interchangeability of medicines across selected European countries, Arhiv za farmaciju, Vol. 74, No. 4, pp. 540 - 555, Aug, 2024
Population exposure-response model of 131I in patients with benign thyroid disease (2021-10)

V. Topić Vučenović, Z. Rajkovača, D. Jelić, D. Stanimirović, M. Mikov, B. Miljković, K. Vučićević, Population exposure-response model of 131I in patients with benign thyroid disease, EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, Vol. 165, pp. 105942 - 105942, Oct, 2021
The influence of biologically effective dose (BED) on the 131I therapy response in patients with benign thyroid disease – nonlinear mixed effect modelling approach (2021-01)

V. Topić Vučenović, Z. Rajkovača, D. Jelić, D. Stanimirović, M. Mikov, B. Miljković, K. Vučićević, The influence of biologically effective dose (BED) on the 131I therapy response in patients with benign thyroid disease – nonlinear mixed effect modelling approach, https://www.paganz.org/abstracts/the-influence-of-biologically-effective-dose-bed-on-the-131i-therapy-response-in-patients-with-benign-thyroid-disease-nonlinear-mixed-effect-modelling-approach/, Jan, 2021
Joint population pharmacokinetic model for clopidogrel and its inactive carboxylic acid metabolite (2024-06)

Z. Pejčić, V. Topić Vučenović, B. Miljković, K. Vučićević, Joint population pharmacokinetic model for clopidogrel and its inactive carboxylic acid metabolite, PAGE 32 (2024) Abstr 11208 [www.page-meeting.org/?abstract=11208], Jun, 2024

Unosi

Population Pharmacokinetic Model of Linezolid and Probability of Target Attainment in Patients with COVID-19-Associated Acute Respiratory Distress Syndrome on Veno-Venous Extracorporeal Membrane Oxygenation—A Step toward Correct Dosing (2024-02)

Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study (2024-05)

Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics) (2018)

Izazovi i stavovi o doziranju radioaktivnog joda u terapiji benignih oboljenja štitne žlijezde (2018-04)

Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach (2018-05)

Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics) (2018-12)

Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients (2020)

Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients (2020-06)

Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice (2021-08)

Nonlinear mixed effects modelling approach for investigation of 131I in patients with benign thyroid disease (2017)

Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease (2017-06)

Investigation of influence of anti-thyroid drug discontinuation time on 131I biokinetics in patients with benign thyroid disease (2017-10)

Investigation of the influence of functional thyroide volumen on the probability of 131 I therapy outcome in patients with benign thyroide disease (2018)

Prediction of the radioiodine therapy outcomes in patients with benign thyroid disease based on pre-therapeutic dosimetry (2018-09)

Integrating Clopidogrel's First-Pass Effect in a Joint Semi-Physiological Population Pharmacokinetic Model of the Drug and Its Inactive Carboxylic Acid Metabolite (2024-05)

Review of lists and recommendations for interchangeability of medicines across selected European countries (2024-08)

Population exposure-response model of 131I in patients with benign thyroid disease (2021-10)

The influence of biologically effective dose (BED) on the 131I therapy response in patients with benign thyroid disease – nonlinear mixed effect modelling approach (2021-01)

Joint population pharmacokinetic model for clopidogrel and its inactive carboxylic acid metabolite (2024-06)